18F-FTC-146 PET/CT in Newly-Diagnosed Osteosarcoma

Not Recruiting

Trial ID: NCT04365660


The purpose of this research is to evaluate the study drug, 18F FTC-146, as a positron emission tomography (PET) / computed tomography (CT) radiotracer imaging agent to evaluate tumor status in patients newly diagnosed with osteosarcoma ("bone cancer").

Official Title

A Phase 2 Study of 18F FTC 146 PET/CT in Patients With Newly Diagnosed Osteosarcoma

Stanford Investigator(s)

Kristen N Ganjoo
Kristen N Ganjoo

Professor of Medicine (Oncology)


Inclusion Criteria:

   - Patients with biopsy proven osteosarcoma requiring local surgical intervention.

   - ECOG ≤ 2

   - Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

   - Chemotherapy in the past 2 months.

   - Prior history of allergic reaction to 18F FTC 146.

   - Pregnant or nursing


drug: 18-F FTC 146

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Denise Montes

New Trial Alerts